| 1356 |
National Cancer Institute |
Html |
en |
Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of metastatic cancer that has spread from an unidentified primary tumor. |
| general cancer information | 0.411851 |
| treatment | 0.656267 |
| cancer treatment | 0.493001 |
| breast cancer cells | 0.486603 |
| primary cancer | 0.600191 |
| new cancer treatments | 0.408458 |
| Peritoneal Cancer Treatment | 0.426103 |
| cancer cells | 0.712358 |
| tissue | 0.443805 |
| malignant tumor cells | 0.423112 |
| body | 0.560831 |
| type | 0.447878 |
| Cancer Information Service | 0.414189 |
| Squamous Neck Cancer | 0.400297 |
| PDQ cancer information | 0.512966 |
| clinical trial search | 0.39505 |
| treatment clinical trials | 0.437756 |
| certain changes | 0.407705 |
| National Cancer Institute | 0.54586 |
| clinical trials | 0.823063 |
| normal cells | 0.410928 |
| cancer information summary | 0.471688 |
| clinical trial | 0.588388 |
| new treatment | 0.44726 |
|
| breast cancer prevention | 0.400005 |
| primary cancer site | 0.517081 |
| cancer tissue | 0.403216 |
| patients | 0.429603 |
| Cancer Care page | 0.397493 |
| PDQ summary | 0.435669 |
| treatment clinical trial | 0.401935 |
| PDQ Adult Treatment | 0.398071 |
| NCI PDQ cancer | 0.432436 |
| cancer research process | 0.400715 |
| cancer clinical trials | 0.44656 |
| tests | 0.388491 |
| lymph nodes | 0.409196 |
| Unknown Primary Treatment | 0.395812 |
| carcinoma | 0.39749 |
| primary cancer depend | 0.439856 |
| lymph node | 0.431668 |
| radiation therapy | 0.485838 |
| Treatment Editorial Board | 0.413559 |
| cancer information summaries | 0.411898 |
| comprehensive cancer information | 0.411754 |
| cancer | 0.945761 |
| standard treatment | 0.426236 |
|
CLICK HERE |
| 1675 |
National Cancer Institute |
Html |
en |
Lymphedema (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the anatomy, pathophysiology, clinical manifestations, diagnosis, and treatment of cancer-related lymphedema, a condition in which lymph fluid builds up in tissues and causes swelling. |
| upper-limb lymphedema | 0.596897 |
| Manual lymphatic therapy | 0.494091 |
| axillary node dissection | 0.485114 |
| lymph nodes. | 0.472628 |
| upper-extremity lymphedema | 0.68666 |
| arm lymphedema | 0.638618 |
| lower-limb lymphedema | 0.630542 |
| lymph node dissection | 0.832229 |
| lower-extremity lymphedema | 0.630897 |
| deep lymphatic systems | 0.498654 |
| intestinal lymphatic trunk | 0.501781 |
| new lymphedema | 0.619269 |
| lumbar lymphatic trunk | 0.502509 |
| upper extremity lymphedema | 0.623186 |
| manual lymphatic drainage | 0.477215 |
| lymph collector vessels | 0.497637 |
| lymphatic vessels | 0.762836 |
| lymphedema onset | 0.622585 |
| secondary lymphedema | 0.644407 |
| certified lymphedema | 0.696216 |
| left subclavian vein | 0.475686 |
| lymphedema manifest | 0.633761 |
| lymphedema classification | 0.594846 |
| protein-rich lymph fluid | 0.533977 |
|
| secondary lymphatic vessels | 0.59679 |
| subclavian lymphatic trunk | 0.576658 |
| primary lymphatic vessels | 0.596665 |
| subcutaneous lymphatic vessels | 0.50703 |
| lymphedema | 0.987634 |
| breast cancer patients | 0.473019 |
| certified lymphedema therapist | 0.652056 |
| patients | 0.478875 |
| cancer patients | 0.474035 |
| Lymph channels | 0.46738 |
| lymph node biopsy | 0.634545 |
| breast cancer | 0.848001 |
| sentinel lymph node | 0.728941 |
| certified lymphedema therapists | 0.649954 |
| unidirectional lymphatic flow | 0.496065 |
| breast cancer survivors | 0.505056 |
| axillary lymph node | 0.799687 |
| lymph nodes | 0.59192 |
| treatable lymphedema | 0.590609 |
| lymph node biopsy. | 0.539242 |
| manual lymphedema therapy. | 0.64813 |
| lymph node drainage | 0.539621 |
| manual lymphedema therapy | 0.852751 |
|
CLICK HERE |
| 1687 |
National Cancer Institute |
Html |
en |
Gastrointestinal Stromal Tumors Treatment (PDQ®)–Patient Version |
Gastrointestinal stromal tumors (GIST) are usually found on the stomach or small intestine, but they can be found anywhere in or near the GI tract. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for gastrointestinal stromal tumors. |
| currently used treatment | 0.490034 |
| treatment | 0.783421 |
| cancer treatment | 0.523117 |
| magnetic resonance imaging | 0.511967 |
| new cancer treatments | 0.495454 |
| gastrointestinal stromal tumors | 0.803015 |
| cancer cells | 0.659955 |
| cancer spreads | 0.50304 |
| body | 0.629918 |
| imatinib mesylate | 0.539824 |
| Cancer Information Service | 0.497222 |
| treatment clinical trial | 0.508389 |
| PDQ cancer information | 0.611396 |
| specific cancer cells | 0.500865 |
| tyrosine kinase inhibitors | 0.510959 |
| treatment clinical trials | 0.542788 |
| National Cancer Institute | 0.565368 |
| clinical trials | 0.968461 |
| GISTs | 0.508373 |
| GI tract | 0.557476 |
| cancer information summary | 0.563972 |
| new treatment | 0.580544 |
| detailed pictures | 0.514969 |
| patients | 0.508785 |
|
| Blood. The cancer | 0.489451 |
| metastatic tumor | 0.505075 |
| following tests | 0.492889 |
| nuclear magnetic resonance | 0.514044 |
| PDQ summary | 0.507052 |
| Stromal Tumors Treatment | 0.504624 |
| PDQ Adult Treatment | 0.502889 |
| clinical trial | 0.717659 |
| malignant tumor cells | 0.539522 |
| NCI PDQ cancer | 0.516596 |
| cancer research process | 0.486456 |
| cancer clinical trials | 0.513219 |
| gastrointestinal stromal tumor | 0.560708 |
| supportive care | 0.528752 |
| Treatment Editorial Board | 0.52414 |
| treatment options | 0.517296 |
| cancer information summaries | 0.495697 |
| comprehensive cancer information | 0.495617 |
| parts | 0.488573 |
| cancer | 0.897871 |
| standard treatment | 0.510757 |
| small intestine | 0.49775 |
| watchful waiting | 0.49459 |
|
CLICK HERE |
| 1765 |
National Cancer Institute |
Html |
en |
Physical Activity and Cancer |
A fact sheet that summarizes evidence linking exercise and other physical activity, including work and household chores, to reduced cancer risks. |
| U. Physical activity | 0.367372 |
| bone-strengthening physical activity | 0.370971 |
| physical activity daily | 0.371076 |
| physical activity attenuate | 0.362897 |
| better breast cancer | 0.3594 |
| low physical activity | 0.37763 |
| Breast Cancer Research | 0.357155 |
| muscle-strengthening physical activity | 0.370998 |
| vigorous physical activity | 0.364437 |
| S. Physical activity | 0.365821 |
| average breast cancer | 0.365315 |
| cancer risk reduction | 0.373439 |
| colorectal cancer | 0.41572 |
| average endometrial cancer | 0.357301 |
| H. Physical activity | 0.366033 |
| postdiagnosis physical activity | 0.363749 |
| postmenopausal breast cancer | 0.379275 |
| lower risk | 0.357009 |
| potential physical activity | 0.369413 |
| physical activity influence | 0.360893 |
| different cancer risk | 0.360424 |
| aerobic physical activity | 0.386234 |
| vigorous-intensity physical activity | 0.373987 |
| cancer survivors | 0.406644 |
| Cancer Epidemiology | 0.363652 |
|
| cancer prevention | 0.376861 |
| Physical Activity website | 0.371276 |
| A. Physical activity | 0.364619 |
| breast cancer diagnosis | 0.4205 |
| endometrial cancer risk | 0.390992 |
| breast cancer recurrence | 0.359315 |
| Physical Activity Guidelines | 0.371598 |
| links physical activity | 0.369787 |
| physical activity benefit | 0.375758 |
| National Cancer Institute | 0.363045 |
| daily physical activity | 0.370902 |
| L. Physical activity | 0.366831 |
| breast cancer risk | 0.390634 |
| colon cancer | 0.375643 |
| meta-analysis | 0.376142 |
| breast cancer | 0.54813 |
| colon cancer risk | 0.372667 |
| systematic review | 0.435657 |
| physical activity | 0.996162 |
| prostate cancer | 0.369869 |
| leisure-time physical activity | 0.442557 |
| et al | 0.539243 |
| cancer risk | 0.441434 |
| recreational physical activity | 0.391568 |
|
CLICK HERE |
| 2068 |
National Cancer Institute |
Html |
es |
Marcadores de tumores |
Hoja informativa que explica lo que son los marcadores de tumores y responde preguntas sobre su uso para el diagnóstico y tratamiento del cáncer. |
| Bast RC Jr | 0.727949 |
| cancer screening | 0.603977 |
| Gray RJ | 0.462067 |
| randomized european study | 0.51305 |
| Asociación Estadounidense | 0.468124 |
| estudio plco | 0.461327 |
| Bigbee W | 0.467579 |
| amplia gama | 0.464843 |
| afecciones benignas | 0.671952 |
| Herberman RB | 0.469893 |
| Prevention Research | 0.463207 |
| BC Decker Inc | 0.509079 |
| Clinical Laboratory Improvement | 0.519898 |
| Cancer Screening Randomized | 0.544857 |
| Controlled Trial | 0.467216 |
| riesgo intermedio | 0.462476 |
| Clinical Practice | 0.47196 |
| ecografÃa transvaginal | 0.471751 |
| Makower DF | 0.466396 |
| estudio tailorx | 0.460805 |
| ¿Cuáles marcadores | 0.637902 |
| 21-gene expression assay | 0.514014 |
|
| Hugosson J | 0.463892 |
| Instituto Nacional | 0.461324 |
| screening trial specimens | 0.541412 |
| OncologÃa ClÃnica | 0.463202 |
| tumor markers | 0.619108 |
| Andriole G | 0.463781 |
| Mortality results from | 0.526447 |
| Quality Requirements | 0.470424 |
| Kufe DW | 0.468535 |
| Black A | 0.461077 |
| 6th ed | 0.467056 |
| Oncotype DX® | 0.469566 |
| situaciones benignas | 0.492829 |
| PubMed Abstract | 0.928354 |
| tratamientos resultantes | 0.466203 |
| Buys SS | 0.460749 |
| BioquÃmica ClÃnica | 0.461341 |
| Pollock RE | 0.46616 |
| New England Journal | 0.930005 |
| Roobol MJ | 0.466517 |
| Sparano JA | 0.466154 |
| hoja informativa estadificación | 0.539118 |
|
CLICK HERE |
| 2069 |
National Cancer Institute |
Html |
es |
Enfermedad de Paget de seno |
Hoja informativa sobre la enfermedad de Paget de seno, un tipo poco común de cáncer que algunas veces se llama enfermedad de Paget del pezón o enfermedad de Paget de mama. |
| Lippincott Williams | 0.227873 |
| Tumor Characteristics | 0.23784 |
| Eisner MP | 0.227823 |
| cáncer invasor | 0.852818 |
| afecciones benignas | 0.232299 |
| Cody HS | 0.226638 |
| Female Breast | 0.245015 |
| posibles tumores | 0.243494 |
| long-term follow-up study | 0.244429 |
| Breast Cancer Research | 0.268606 |
| siglo xix sir | 0.249073 |
| breast-conserving therapy | 0.228801 |
| Lippman ME | 0.226791 |
| ganglios linfáticos centinela | 0.294176 |
| afección benigna | 0.309089 |
| SEER Program | 0.276615 |
| Kanitakis J | 0.22651 |
| estadio i | 0.22947 |
| Hasson D | 0.226314 |
| European Institute | 0.226377 |
| Keel GE | 0.226988 |
| PubMed Abstract | 0.996634 |
| Haffty BG | 0.225876 |
| clinical presentation | 0.228015 |
| Therapeutic options | 0.226841 |
|
| with radiotherapy | 0.228051 |
| Tucker SL | 0.226414 |
| Paget mamaria | 0.499743 |
| estadio iv | 0.228625 |
| End Results | 0.22623 |
| Griffith KA | 0.226914 |
| signo revelador | 0.231703 |
| proteÃna her2 | 0.228884 |
| National Cancer Institute | 0.247867 |
| 4th ed | 0.228822 |
| Sosnovskikh I | 0.226721 |
| Ries LAG | 0.280943 |
| edad promedio | 0.227469 |
| Breast Journal | 0.241614 |
| Osborne CK | 0.226941 |
| Sir James Paget | 0.694935 |
| Cancer Survival Among | 0.251885 |
| estadio iii | 0.228362 |
| Gatti G | 0.22751 |
| Retrieved April | 0.227819 |
| sentinel lymph | 0.278815 |
| European Academy | 0.22756 |
| extramammary paget | 0.443981 |
| Dimaio DJ | 0.226799 |
|
CLICK HERE |
| 3441 |
National Cancer Institute |
Html |
es |
Exámenes de detección del neuroblastoma (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el neuroblastoma. |
| Berthold F | 0.326193 |
| mass screening | 0.922436 |
| Tuchman M | 0.34781 |
| Children may not | 0.324022 |
| neuroblastoma mortality | 0.351312 |
| Woods WG | 0.492877 |
| localized neuroblastoma detected | 0.404842 |
| Parker L | 0.323694 |
| may not benefit | 0.324348 |
| Cancer Screening | 0.425638 |
| chemical screening | 0.340948 |
| Yamamoto K | 0.365979 |
| benefit from neuroblastoma | 0.405641 |
| through mass screening | 0.347656 |
| PDQ Exámenes | 0.326687 |
| Hanada R | 0.340494 |
| mass screening system | 0.350977 |
| with neuroblastoma detected | 0.349391 |
| mass screening program | 0.35097 |
| Chamberlain J | 0.321084 |
| not benefit from | 0.325375 |
| Schilling FH | 0.328231 |
| Matsumura T | 0.318421 |
| German Neuroblastoma Screening | 0.39432 |
| with neuroblastoma | 0.385081 |
|
| Oncology Group study | 0.324277 |
| Neuroblastoma Cooperative Study | 0.352151 |
| Kluwer Academic Publishers | 0.324031 |
| childhood neuroblastoma death | 0.391312 |
| urinary mass screening | 0.348636 |
| Neuroblastoma mass screening | 0.390256 |
| neuroblastoma through mass | 0.359101 |
| Quebec Neuroblastoma Screening | 0.468726 |
| neuroblastoma detected | 0.476634 |
| from neuroblastoma screening | 0.464226 |
| childhood neuroblastoma | 0.424072 |
| Pediatr Hematol Oncol | 0.393544 |
| Med Pediatr Oncol | 0.517922 |
| Clin Oncol | 0.429185 |
| Neuroblastoma trends | 0.350168 |
| neuroblastoma without | 0.349525 |
| or metastatic neuroblastoma | 0.348237 |
| for screening | 0.34682 |
| Takeda T | 0.332537 |
| Pediatric Oncology Group | 0.318607 |
| Spix C | 0.326336 |
| Neuroblastoma Screening Project | 0.535562 |
| neuroblastomas detected through | 0.332839 |
| neuroblastoma screening | 0.923332 |
|
CLICK HERE |
| 3582 |
National Cancer Institute |
Html |
en |
Frederick National Laboratory for Cancer Research |
The FNLCR combines private sector business practices with government infrastructure to conduct research and development in cancer and AIDS. |
| Frederick National Lab | 0.679634 |
| Development Center—one | 0.586036 |
| Federally Funded Research | 0.723777 |
| FNLCR | 0.617129 |
| biomarker identification | 0.53533 |
| animal sciences | 0.53568 |
| national resource | 0.541398 |
| government agencies | 0.530109 |
| human clinical trials | 0.61809 |
| preclinical assay development | 0.712354 |
| oncology-focused computational science | 0.628628 |
| cancer research laboratories | 0.757218 |
| early development | 0.553877 |
| research reagents | 0.571396 |
| NCI | 0.666268 |
| genetically engineered mouse | 0.603734 |
| preclinical research | 0.638044 |
| nonprofit research organizations | 0.690454 |
| broad charter | 0.538883 |
| Leidos Biomedical Research | 0.735212 |
| United States | 0.647036 |
| Nanotechnology Characterization Laboratory | 0.625355 |
| RAS family | 0.527528 |
| clinical practice | 0.533965 |
|
| NCI investigators | 0.632716 |
| significant cancer research | 0.722685 |
| translational genomics | 0.544933 |
| cancer research | 0.952491 |
| private sector business | 0.653242 |
| new drug development | 0.647375 |
| government sponsors | 0.545164 |
| biomedical research community | 0.670235 |
| development needs | 0.584975 |
| cancer researchers | 0.562687 |
| clinical operations | 0.542191 |
| Frederick National Laboratory | 0.684108 |
| government infrastructure | 0.535486 |
| technical staff | 0.530406 |
| preclinical model development | 0.704349 |
| private sector resources | 0.635668 |
| FNLCR programs | 0.564698 |
| National lab staff | 0.628876 |
| biomedical computing | 0.548325 |
| new cancer therapies | 0.637914 |
| frozen tumor samples | 0.605424 |
| nanotechnology applications | 0.53469 |
| cancer research enterprise | 0.705608 |
| basic research | 0.59861 |
|
CLICK HERE |
| 16886 |
National Cancer Institute |
Html |
en |
Thyroid Cancer Screening (PDQ®)–Health Professional Version |
Expert-reviewed information summary about tests used to detect or screen for thyroid cancer. |
| thyroid cancer trends | 0.476323 |
| thyroid tumors | 0.422645 |
| United States | 0.468063 |
| thyroid cancer screening. | 0.46539 |
| cancer registry data | 0.363099 |
| thyroid fine-needle aspiration | 0.447959 |
| opportunistic thyroid cancer | 0.46743 |
| thyroid cancer | 0.931034 |
| thyroid cancer incidence | 0.631162 |
| Thyroid Cancer Treatment | 0.500772 |
| Well-differentiated thyroid cancers | 0.495048 |
| palpation screening results | 0.370878 |
| total thyroidectomy | 0.358528 |
| cancer screening results | 0.386186 |
| radioactive iodine | 0.350234 |
| South Korea | 0.456219 |
| 10-year relative survival | 0.451331 |
| frequently diagnosed cancer | 0.37852 |
| recurrent laryngeal nerve | 0.36801 |
| papillary thyroid cancer | 0.525506 |
| summary event measure | 0.364067 |
| free screening exams | 0.364504 |
| follicular thyroid cancers | 0.495803 |
| thyroid cancer mortality | 0.490522 |
|
| thyroid cancer overdiagnosis | 0.479797 |
| neck palpation | 0.364787 |
| cancer incidence rates | 0.389027 |
| thyroid cancer deaths. | 0.489306 |
| thyroid cancers cases | 0.461202 |
| thyroid cancer cases | 0.467037 |
| papillary thyroid cancers | 0.524728 |
| cancer diagnoses | 0.354076 |
| anaplastic thyroid cancers | 0.495303 |
| laryngeal nerve injury | 0.368292 |
| thyroid cancer screening | 0.828908 |
| thyroid cancers | 0.597668 |
| thyroid ultrasound | 0.428817 |
| suspicious screening result | 0.361018 |
| thyroid surgery | 0.435882 |
| population-based screening programs | 0.366887 |
| national cancer screening | 0.412147 |
| medullary thyroid cancer | 0.491568 |
| Cancer Screening Guidelines | 0.39228 |
| formal screening | 0.347128 |
| asymptomatic thyroid cancers | 0.481523 |
| incidental thyroid nodules | 0.466527 |
| vocal cord | 0.353855 |
|
CLICK HERE |
| 17282 |
National Cancer Institute |
Html |
es |
Opciones para su atención médica si el tratamiento puede no ser una opción |
Diferentes pacientes tienen metas de atención diferentes. Evalúe sus opciones de atención médica una vez se entere que tiene cáncer avanzado. |
| experta atención | 0.942071 |
| Palliative Care Organization | 0.880871 |
| situación mejora | 0.828197 |
|
| corto plazo | 0.853503 |
| sentimientos frente | 0.970266 |
|
CLICK HERE |